Benefits of Antibody Drug Conjugates for Multiple Myeloma, with Dr. Chakraborty

DocWire News spoke with Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, Division of Hematology/Oncology, on the benefits of antibody drug conjugates (ADC) for multiple myeloma.

This is the fourth in a four part conversation on treatments for multiple myeloma with Dr. Chakraborty. Watch part one, on recent clinical trials for newly-diagnosed disease, part two, on the challenges of the paradigm shift to quadruplet therapy, and part three, on bispecific T-cell engagers (BiTEs).